Over 500 people have complained of side effects from the reformulation of a commonly used drug, prompting calls for alternatives to be made available.
In June health authorities announced they were urgently investigating problems with Eltroxin, a hyporthyroidism drug taken by 70,000 New Zealanders.
Their action followed a rash of reports of nausea, headaches and weight gain, since the drug was reformulated by manufacturer GlaxoSmithKline (GSK) over a year ago.
At the time, Medsafe head Stewart Jessamine said the drug had been dispensed since July last year and the same reformulation had been used in Germany for 18 months without problems.
Medsafe was considering the possibility there was a problem with the current batch of the drug available in New Zealand.
As a result of the complaints instructions on how the drug should be taken had changed.
But Green Party health spokeswoman Sue Kedgley said answers to written parliamentary questions showed 571 New Zealanders had reported problems with the drug to the Centre for Adverse Reactions Monitoring so far this year.
On that basis Medsafe should tell GSK the new formulation was not acceptable and seek an alternative drug, she said.
A Health Ministry spokesman said testing had shown no problems with one batch of the drug and Medsafe were awaiting final results from testing of a second batch.
He said bringing in an alternative drug was complicated as a manufacturer had to first want to sell its drug on New Zealand's small market.
Drug subsidy agency Pharmac had carried out some preliminary discussions with alternative suppliers, but with no immediate success.
If a supplier was keen it would then have to put its drug forward for registration.
Hypothyroidism is a condition where the thyroid gland does not produce enough hormones, leading to fatigue and in some cases depression.
This article is tagged with the following keywords. Find out more about MyNBR Tags
- The Rumble: 2015’s IPO drought
- MARKET CLOSE: Shares rise on A2 bounce back; Tower, Genesis attract investors
- High Court hears allegations over redacted report in Trends R&D funding case
- Scentre Group to sell three Westfield malls to NZ firms for $549m
- Parent, widow of Pike River casualties fail to force review of decision to drop charges against Whittall
Most listened to
- Tim Hunter on why Veritas is doing it the hard way
- Matthew Hooton on whether Steven Joyce will be the next national leader
- Rodney Hide on why all city planners should be fired
- Nevil Gibson discusses his latest Editor's Insight on films
- The NBR crew throw around some of the week's top stories
- Rob Hosking breaks down the political and economic week that was
- "A tragedy" - David Farrar on his disappointment with Simon Bridges
- New F&P product pipeline exciting, says Macquarie senior investment adviser Brad Gordon
- Taupo Motorsport Park executive director Tony Walker on the park's rebranding
- NZIER senior economist Christina Leung on why she does not think the OCR will hit 2%
- NBR's Cameron Officer talks about the NBR Car of the Year 2015
- John Barnett on Brewer: ‘Boy, has he got a bit to learn’